Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kenemans

Showing results (191-200 of 235) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|February 1, 1994
Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRIM R Buist, R P Golding, C W Burger, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 17, 1999
Differences between hereditary and sporadic ovarian cancerR P Zweemer, R H Verheijen, F H Menko, et al.
European Journal of Immunology|June 1, 1993
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytesH W Nijman, J G Houbiers, M P Vierboom, et al.
Journal of Internal Medicine|March 12, 2002
Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal womenM S Post, D F Hendriks, M J Van Der Mooren, et al.
International Journal of Cancer|April 3, 2001
Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.pI van Zanten-Przybysz, C F Molthoff, J C Roos, et al.
Clinical Chemistry|June 1, 1993
Evaluation of colorectal cancer-associated mucin CA M43 assay in serumG J van Kamp, S von Mensdorff-Pouilly, P Kenemans, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1992
Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomasC A Yedema, P Kenemans, T Wobbes, et al.
British Journal of Cancer|June 1, 1994
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumoursF V Cromme, P F van Bommel, J M Walboomers, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controlsF G Snijdewint, S von Mensdorff-Pouilly, A H Karuntu-Wanamarta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
Pageof 24

Showing results (191-200 of 235) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|February 1, 1994
Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRIM R Buist, R P Golding, C W Burger, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 17, 1999
Differences between hereditary and sporadic ovarian cancerR P Zweemer, R H Verheijen, F H Menko, et al.
European Journal of Immunology|June 1, 1993
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytesH W Nijman, J G Houbiers, M P Vierboom, et al.
Journal of Internal Medicine|March 12, 2002
Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal womenM S Post, D F Hendriks, M J Van Der Mooren, et al.
International Journal of Cancer|April 3, 2001
Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.pI van Zanten-Przybysz, C F Molthoff, J C Roos, et al.
Clinical Chemistry|June 1, 1993
Evaluation of colorectal cancer-associated mucin CA M43 assay in serumG J van Kamp, S von Mensdorff-Pouilly, P Kenemans, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1992
Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomasC A Yedema, P Kenemans, T Wobbes, et al.
British Journal of Cancer|June 1, 1994
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumoursF V Cromme, P F van Bommel, J M Walboomers, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controlsF G Snijdewint, S von Mensdorff-Pouilly, A H Karuntu-Wanamarta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
Pageof 24